South-Eastern Asia vs Türkiye: Proportion of the target population who received a 3rd dose of
South-Eastern Asia
56.0%
in 2024
Türkiye
95.0%
in 2024
South-Eastern Asia rank
28th
Türkiye rank
28th
Proportion of the target population who received a 3rd dose of over time
- South-Eastern Asia
- Türkiye
How they compare
Türkiye currently reports 95.0% against 56.0% in South-Eastern Asia, a difference of 39.0%.
That makes Türkiye's figure about 1.7 times South-Eastern Asia's.
Across all 16 years both countries report, Türkiye has been ahead every year.
South-Eastern Asia ranks 28th and Türkiye ranks 28th of 37 groups.
Türkiye has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | South-Eastern Asia | Türkiye | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 0.0% | 97.0% | 97.0% | Türkiye |
| 2010s | 9.5% | 96.4% | 86.9% | Türkiye |
| 2020s | 35.6% | 95.2% | 59.6% | Türkiye |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher proportion of the target population who received a 3rd dose of, South-Eastern Asia or Türkiye?
- Türkiye, at 95.0% against 56.0% in South-Eastern Asia as of 2024.
- What is the difference in proportion of the target population who received a 3rd dose of between South-Eastern Asia and Türkiye?
- 39.0%, with Türkiye ahead.
- How many years of comparable data are there for South-Eastern Asia and Türkiye?
- 16 years are reported by both, from 2009 to 2024.
- How do South-Eastern Asia and Türkiye rank globally for proportion of the target population who received a 3rd dose of?
- South-Eastern Asia ranks 28th and Türkiye ranks 28th of 37 groups.
- Where does this data come from?
- United Nations Statistics Division, SDG Global Database, published as Proportion of the target population who received a 3rd dose of pneumococcal conjugate (PCV3) vaccine (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.